Connect your AI

MaxCyte MXCT Change in Other Assets

Change in Other Assets at other companies

Ginkgo BioworksDNA

-$94K-156%

Immix Biopharma, Inc.IMMX

$866.6K+174%

Rapid Micro BiosystemsRPID

$13K—

PDE

Pro-Dex, Inc.PDEX

$186K—

RepligenRGEN

-$26K-102%

Prime MedicinePRME

-$1.22M-255%

Other financials

Income statement

Revenue$9.7M-7.1%

Gross profit$8.1M-9.1%

Operating income-$6.2M+49.7%

Net income-$4.8M+53.7%

EPS (diluted)-$0.04+60.0%

Balance sheet

Cash & equivalents$14.6M-37.8%

Total debt$17.5M-7.1%

Total equity$167.9M-15.8%

Total assets$194.5M-15.4%

Cash flow

Operating cash flow-$8.2M+43.3%

CapEx$72.0K-89.0%

Free cash flow-$8.2M+45.3%

Valuation

Market cap$130.15M-46.8%

Enterprise value$133.08M-46.3%

P/S4×-2.8×

Profitability

Gross margin80.5%-0.4pp

Operating margin-141.8%+6.4pp

Net margin-121.2%+12.3pp

FCF margin-90.9%+3.7pp

Returns & leverage

Return on equity-21.3%+2.0pp

Debt / equity0.1×0.0×

Current ratio12×-0.2×

Where this comes from

Reported directly by MaxCyte in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentAssets.

The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about MaxCyte's change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is MaxCyte's change in other assets?: MaxCyte (MXCT) reported change in other assets of $127K in Q1 2026.
How has MaxCyte's change in other assets changed year-over-year?: MaxCyte's change in other assets decreased by 50.0% year-over-year, from $254K to $127K.
What does change in other assets mean?: Change in miscellaneous assets affecting operating cash flow.